FABP4 FABP5 Expression Assay for GIP Suppression Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for evaluating or selecting agents that suppress glucose-dependent insulinotropic polypeptide (GIP) level elevation are not rapid or highly sensitive, limiting their effectiveness in preventing obesity and improving digestion.
Innovation Solution
A method involving contacting a test substance with mammal-derived tissue or cells expressing FABP4 or FABP5 genes/proteins, measuring their expression or activity, and comparing these to a control group to evaluate and select substances that reduce FABP4/5 expression or activity as agents for suppressing GIP level elevation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods using CPT1 gene/protein expression or FAT/CD36 gene/protein expression are used to evaluate agents for suppressing GIP level elevation, then evaluation can be performed, but the method is not rapid or highly sensitive enough
Solution Approach 1:
The invention changes the evaluation parameter from CPT1 or FAT/CD36 expression to FABP4/5 expression levels. This parameter change enables more rapid and sensitive detection of GIP suppression activity, as FABP4/5 expression can be measured more efficiently and shows stronger correlation with GIP suppression effects than the conventional markers.
2Productivity
If FABP4/5 expression is used as an index to evaluate GIP suppression activity, then rapid and highly sensitive evaluation is achieved, but new evaluation methodology must be developed
Solution Approach 1:
The invention makes the FABP4/5 expression marker universal for evaluating GIP suppression activity across different test substances and experimental conditions. This single marker can evaluate various compounds (chemical substances, extracts, etc.) using the same methodology, simplifying the overall evaluation process despite the novelty of the approach.
Data Source
AI summary
A method for evaluating or selecting an agent for suppressing GIP level elevation, comprising the following steps (A) to (D): (A) contacting a test substance with a mammal-derived tissue or cell capable of expressing an FABP4 gene or FABP5 gene, or an FABP4 protein or FABP5 protein; (B) measuring an expression level of the FABP4 gene or FABP5 gene, an expression level of the FABP4 protein or FABP5 protein, or an activity of the FABP4 protein or FABP5 protein in the mammal-derived tissue or cell; (C) comparing the expression level or activity measured in the above (B) with an expression level of an FABP4 gene or FABP5 gene, an expression level of an FABP4 protein or FABP5 protein, or an activity of an FABP4 protein or FABP5 protein in a control group; and (D) evaluating or selecting a test substance which reduces the expression level of the FABP4 gene or FABP5 gene, the expression level of the FABP4 protein or FABP5 protein, or the activity of the FABP4 protein or FABP5 protein as an agent suppressing GIP level elevation based on results of the above (C).